Characterization of susceptibility profiles for the CCR5 antagonist vicriviroc in treatment-naive HIV-infected subjects

被引：0
|
作者：
Landovitz, R.
Faetkenhauer, G.
Hoffmann, C.
Horst, H.
Strizki, J.
Whitcomb, J.
Gheyas, F.
Knepp, D.
Greaves, W.
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
[2] Univ Cologne, Dept Internal Med, D-5000 Cologne 41, Germany
[3] Hosp St George, Dept Internal Med, Hamburg, Germany
[4] Univ Kiel, Dept Internal Med, D-24098 Kiel, Germany
[5] Monogram Biosci Inc, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2006年 / 11卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [41] HIV-INFECTED TREATMENT-NAIVE INDIVIDUALS HAVE LOW CIRCULATING PROGENITOR CELLS
    Ghasemzadeh, Nima
    Zhang, Lane
    Li, Qunna
    Wirtz, Susan S.
    Hritani, Abdul Wahab
    Kumar, Saket
    Ofotokun, Igho
    Guest, Jodie L.
    Taylor, W. Robert
    Quyyumi, Arshed
    Mavromatis, Kreton
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E1143 - E1143
  • [42] Rhinocerebral zygomycosis in an HIV-infected man during therapy with an investigational CCR5 inhibitor
    Merchant, Shehzad
    Reichman, Richard
    Koval, Christine E.
    AIDS, 2007, 21 (12) : 1666 - 1669
  • [43] Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults
    Lalezari, J
    Thompson, M
    Kumar, P
    Piliero, P
    Davey, R
    Patterson, K
    Shachoy-Clark, A
    Adkison, K
    Demarest, J
    Lou, Y
    Berrey, M
    Piscitelli, S
    AIDS, 2005, 19 (14) : 1443 - 1448
  • [44] Expedient synthesis of MLN1251, a CCR5 antagonist for treatment of HIV
    Ronn, Magnus
    McCubbin, Quentin
    Winter, Steve
    Veige, Melanie K.
    Grimster, Neil
    Alorati, Tony
    Plamondon, Louis
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2007, 11 (02) : 241 - 245
  • [45] Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection
    Klibanov, Olga M.
    Williams, Shannon H.
    Iler, Cameron A.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (08) : 940 - 950
  • [46] Overcoming hERG affinity in the discovery of maraviroc; A CCR5 antagonist for the treatment of HIV
    Price, David A.
    Armour, Duncan
    de Groot, Marcel
    Leishman, Derek
    Napier, Carolyn
    Perros, Manos
    Stammen, Blanda L.
    Wood, Anthony
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (13) : 1140 - 1151
  • [47] Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
    Kravchenko, A. V.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (11) : 125 - +
  • [48] Antiretroviral treatment strategies and immune reconstitution in treatment-naive HIV-infected patients with advanced disease
    Soria, Alessandro
    Lazzarin, Adriano
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 : S19 - S30
  • [49] Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
    Strizki, JM
    Tremblay, C
    Xu, S
    Wojcik, L
    Wagner, N
    Gonsiorek, W
    Hipkin, RW
    Chou, CC
    Pugliese-Sivo, C
    Xiao, YS
    Tagat, JR
    Cox, K
    Priestley, T
    Sorota, S
    Huang, W
    Hirsch, M
    Reyes, GR
    Baroudy, BM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 4911 - 4919
  • [50] The Prevalence of Transmitted Antiretroviral Drug Resistance in Treatment-Naive HIV-Infected Individuals in China
    Liao, Lingjie
    Xing, Hui
    Shang, Hong
    Li, Jingyun
    Zhong, Ping
    Kang, Laiyi
    Cheng, Hua
    Si, Xuefeng
    Jiang, Shulin
    Li, Xinping
    Shao, Yiming
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 : S10 - S14
12345